The estimated Net Worth of Sharon Mates is at least $111 Million dollars as of 29 August 2024. Sharon Mates owns over 70,000 units of Intra-Cellular Therapies Inc stock worth over $82,545,052 and over the last 10 years he sold ITCI stock worth over $24,226,107. In addition, he makes $4,724,560 as Chairman of the Board, President und Chief Executive Officer at Intra-Cellular Therapies Inc.
Sign up
Sharon Mates ITCI stock SEC Form 4 insiders trading
Sharon has made over 36 trades of the Intra-Cellular Therapies Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 70,000 units of ITCI stock worth $891,100 on 29 August 2024.
The largest trade he's ever made was exercising 191,362 units of Intra-Cellular Therapies Inc stock on 16 January 2024 worth over $3,226,363. On average, Sharon trades about 37,180 units every 73 days since 2014. As of 29 August 2024 he still owns at least 1,104,725 units of Intra-Cellular Therapies Inc stock.
You can see the complete history of Sharon Mates stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sharon Mates biography
Dr. Sharon Mates Ph.D. is the Chairman of the Board, President, Chief Executive Officer of Intra-Cellular Therapies, Inc. Dr. Mates has been Chairman, President and Chief Executive Officer of the Company since the Merger in August 2013 and has been the Chairman of the board of directors, President and Chief Executive Officer of ITI since June 2002. Dr. Mates co-founded ITI in May 2002. Prior to co-founding ITI, Dr. Mates was a co-founder of Functional Genetics, and served as its Chairman and Chief Executive Officer from December 2000 until August 2003. From 1989 to 1998, Dr. Mates was the President and a board member of North American Vaccine Inc. and its predecessor companies. Dr. Mates serves on the board of the Biotechnology Innovation Organization (BIO), emerging companies section. Dr. Mates has also served on the Advisory Council of the Center for Society and Health at the Harvard School of Public Health, the Board of Visitors of the Biotechnology Institute of the University of Maryland and the board of directors of Gilda’s Club of New York. Earlier in her career, Dr. Mates spent several years as a research analyst and investment banker, and as an advisor to the life sciences industry. Dr. Mates received her B.S. from the Ohio State University and her Ph.D. from the University of Washington, and completed her postdoctoral fellowships at The Massachusetts General Hospital and Harvard Medical School.
What is the salary of Sharon Mates?
As the Chairman of the Board, President und Chief Executive Officer of Intra-Cellular Therapies Inc, the total compensation of Sharon Mates at Intra-Cellular Therapies Inc is $4,724,560. There are no executives at Intra-Cellular Therapies Inc getting paid more.
How old is Sharon Mates?
Sharon Mates is 67, he's been the Chairman of the Board, President und Chief Executive Officer of Intra-Cellular Therapies Inc since 2014. There are 4 older and 11 younger executives at Intra-Cellular Therapies Inc. The oldest executive at Intra-Cellular Therapies Inc is Richard Lerner, 81, who is the Independent Director.
What's Sharon Mates's mailing address?
Sharon's mailing address filed with the SEC is C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK, NY, 10016.
Insiders trading at Intra-Cellular Therapies Inc
Over the last 11 years, insiders at Intra-Cellular Therapies Inc have traded over $77,703,646 worth of Intra-Cellular Therapies Inc stock and bought 3,068,522 units worth $52,322,638 . The most active insiders traders include Rory B Riggs, Joel S Marcus und Christopher D Alafi. On average, Intra-Cellular Therapies Inc executives and independent directors trade stock every 17 days with the average trade being worth of $2,787,280. The most recent stock trade was executed by Sharon Mates on 29 August 2024, trading 70,000 units of ITCI stock currently worth $891,100.
What does Intra-Cellular Therapies Inc do?
intra-cellular therapies is a company based out of 3960 broadway, new york, new york, united states.
What does Intra-Cellular Therapies Inc's logo look like?
Complete history of Sharon Mates stock trades at Intra-Cellular Therapies Inc
Intra-Cellular Therapies Inc executives and stock owners
Intra-Cellular Therapies Inc executives and other stock owners filed with the SEC include:
-
Sharon Mates,
Chairman of the Board, President, Chief Executive Officer -
Mark Neumann,
Executive Vice President, Chief Commercial Officer -
Michael Halstead,
Executive Vice President, General Counsel and Secretary -
Lawrence Hineline,
Chief Financial Officer, Senior Vice President - Finance, Treasurer, Assistant Secretary -
Robert Davis,
Senior Vice President and Chief Scientific Officer -
Kimberly Vanover,
Senior Vice President, Early Stage Clinical Development and Translational Medicines -
Dr. Sharon Mates,
Co-Founder, Chairman, CEO & Pres -
Mark Neumann,
EVP & Chief Commercial Officer -
Michael I. Halstead J.D.,
Exec. VP, Gen. Counsel & Sec. -
Dr. Suresh K. Durgam M.D.,
Sr. VP & Chief Medical Officer -
Lawrence J. Hineline CPA, CPA,
Sr. VP of Fin., CFO, Treasurer & Assistant Sec. -
Robert Van Nostrand,
Lead Independent Director -
Joel Marcus,
Independent Director -
Christopher Alafi,
Independent Director -
Rory Riggs,
Independent Director -
Richard Lerner,
Independent Director -
Michael Olchaskey,
Senior Vice President, Head of Regulatory Affairs -
Suresh Durgam,
Chief Medical Officer -
John Bardi,
Senior Vice President - Market Access, Policy and Government Affairs -
Karen Patruno Sheehy Esq.,
Sr. VP & Chief Compliance Officer -
Juan Fernando Sanchez,
VP of Corp. Communications & Investor Relations -
Dr. Robert E. Davis Ph.D.,
Sr. VP & Chief Scientific Officer -
Moshe Alafi,
10% owner -
Capital Co Llc Alafi,
10% owner -
Juan F. Sanchez,
VP, Corp. Communications & IR -
Allen A. Fienberg,
VP of Business Development -
Lawrence P. Wennogle,
Vice President, Drug Discovery -
Michael Rawlins,
Director -
Eduardo Rene Salas,
-
Sanjeev Narula,
Executive Vice President & CFO